Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has earned a consensus rating of “Hold” from the nine research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $61.60.
Several analysts have commented on TTPH shares. Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Sunday, August 11th. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Finally, HC Wainwright cut shares of Tetraphase Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, September 3rd.
TTPH stock traded up $0.03 during mid-day trading on Friday, hitting $3.76. The company had a trading volume of 36,121 shares, compared to its average volume of 110,928. The company has a market capitalization of $10.32 million, a price-to-earnings ratio of -0.14 and a beta of 2.46. Tetraphase Pharmaceuticals has a 12-month low of $3.36 and a 12-month high of $54.40. The company has a quick ratio of 3.95, a current ratio of 4.10 and a debt-to-equity ratio of 0.70. The company has a 50-day moving average price of $1.56 and a 200 day moving average price of $0.95.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($8.40) EPS for the quarter, missing the consensus estimate of ($7.60) by ($0.80). The company had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $2.13 million. Tetraphase Pharmaceuticals had a negative return on equity of 118.65% and a negative net margin of 1,072.60%. As a group, analysts expect that Tetraphase Pharmaceuticals will post -26.55 EPS for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Tetraphase Pharmaceuticals by 803.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 116,428 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 103,544 shares in the last quarter. Edmond DE Rothschild Holding S.A. raised its position in shares of Tetraphase Pharmaceuticals by 90.9% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 210,000 shares of the biopharmaceutical company’s stock valued at $281,000 after buying an additional 100,000 shares in the last quarter. Paloma Partners Management Co purchased a new stake in shares of Tetraphase Pharmaceuticals during the 2nd quarter valued at about $115,000. Jane Street Group LLC purchased a new stake in shares of Tetraphase Pharmaceuticals during the 2nd quarter valued at about $122,000. Finally, Royce & Associates LP raised its position in shares of Tetraphase Pharmaceuticals by 10.7% during the 1st quarter. Royce & Associates LP now owns 527,900 shares of the biopharmaceutical company’s stock valued at $707,000 after buying an additional 51,000 shares in the last quarter.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Further Reading: Special Dividends
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.